XML 132 R124.htm IDEA: XBRL DOCUMENT v3.22.0.1
Restatement of Previously Issued Condensed Financial Statements - Statement of Cash Flows (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss $ 55,951 $ 129,633    
Depreciation and amortization 131,654 51,441    
Deferred income tax benefit 163 4,214    
Share-based Compensation 1,190 16,502    
Fair Value Adjustment of Warrants (51,215) 55,632    
Increase (Decrease) in Deferred Charges 2,332 1,008    
Other Noncash Income (Expense) 3,494 (7,015)    
Increase (Decrease) in Accounts Receivable 44,221 29,279    
Increase (Decrease) in Prepaid Expense (7,170) (7,349)    
Increase (Decrease) in Other Noncurrent Assets (927) 54,644    
Accounts payable 13,746 758    
Deferred revenues 65,988 40,726    
Operating lease right of use assets 7,468 5,919    
Operating lease liabilities (25,666) (5,876)    
Other liabilities (883) (52,109)    
Net Cash Provided by (Used in) Operating Activities 174,037 46,106    
Capital expenditures (32,972) (19,395)    
Payments to Acquire Businesses, Net of Cash Acquired 433 (885,323)    
Proceeds from sale of product line, net of restricted cash 0 3,751    
Net Cash Provided by (Used in) Investing Activities (32,539) (900,967)    
Principal payments on term loan (7,150) (3,150)    
Repayments of Long-term Lines of Credit 0 (65,000)    
Payments of Debt Issuance Costs 0 (5,014)    
Payment for Contingent Consideration Liability, Financing Activities 0 (4,115)    
Proceeds from issuance of debt 0 360,000    
Proceeds from issuance of ordinary shares 0 540,597    
Proceeds from warrant exercises 0 277,526    
Proceeds from stock options exercised 5,074 1,182    
Payments related to tax withholding for stock-based compensation (4,489) (10,420)    
Net cash (used in) provided by financing activities (6,565) 1,091,606    
Effects of exchange rates 8,578 (2,013)    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 143,511 234,732    
Cash and cash equivalents 399,006 308,021 $ 257,730 $ 76,130
Restricted cash 16,913 2,850 14,678 9
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 415,919 310,871 272,408 76,139
Cash paid for interest 27,334 11,405    
Cash paid for income tax 2,583 4,797    
Capital expenditures included in accounts payable 6,138 9,528    
Mark to Market Loss on Contingent Shares 25,085 (1,187)    
Accrued expenses and other current liabilities 29,082 (13,222)    
Previously Reported        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss 23,954 74,001    
Depreciation and amortization 131,654 51,441    
Deferred income tax benefit 162 4,214    
Share-based Compensation 10,479 16,502    
Fair Value Adjustment of Warrants (51,215) 0    
Increase (Decrease) in Deferred Charges 2,332 1,008    
Other Noncash Income (Expense) 3,494 (7,015)    
Increase (Decrease) in Accounts Receivable 44,221 29,279    
Increase (Decrease) in Prepaid Expense (7,170) (7,349)    
Increase (Decrease) in Other Noncurrent Assets (927) 54,644    
Accounts payable 13,746 758    
Deferred revenues 65,988 40,726    
Operating lease right of use assets 7,468 5,919    
Operating lease liabilities (25,666) (5,876)    
Other liabilities (2,839) (52,109)    
Net Cash Provided by (Used in) Operating Activities 174,037 46,106    
Capital expenditures (32,972) (19,395)    
Payments to Acquire Businesses, Net of Cash Acquired 433 (885,323)    
Proceeds from sale of product line, net of restricted cash   3,751    
Net Cash Provided by (Used in) Investing Activities (32,539) (900,967)    
Principal payments on term loan (7,150) (3,150)    
Repayments of Long-term Lines of Credit   (65,000)    
Payments of Debt Issuance Costs   (5,014)    
Payment for Contingent Consideration Liability, Financing Activities   (4,115)    
Proceeds from issuance of debt   360,000    
Proceeds from issuance of ordinary shares   540,597    
Proceeds from stock options exercised 5,074      
Payments related to tax withholding for stock-based compensation (4,489) (10,420)    
Net cash (used in) provided by financing activities (6,565) 1,091,606    
Effects of exchange rates 8,578 (2,013)    
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 143,511 234,732    
Cash and cash equivalents 399,006 308,021 257,730 76,130
Restricted cash 13,513 2,850 11,278 9
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 412,519 310,871 $ 269,008 $ 76,139
Cash paid for interest 27,334 11,405    
Cash paid for income tax 2,583 4,797    
Capital expenditures included in accounts payable 6,138 9,528    
Mark to Market Loss on Contingent Shares 27,680 (1,187)    
Accrued expenses and other current liabilities $ (9,725) (12,035)    
Revision of Prior Period, Error Correction, Adjustment        
Error Corrections and Prior Period Adjustments Restatement [Line Items]        
Net loss   (55,632)    
Fair Value Adjustment of Warrants   $ 55,632